Clinical trials: High-risk Locally Advanced
Rectal Adenocarcinoma, High-risk Locally Advanced
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
This study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk…
- Conditions
- Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy
- Trial name
- STAR (NCT07669220)
- Testing
- Short-course Radiotherapy, SCRT, Toripalimab
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic…
- Trial name
- NCT05009290
- Testing
- SHR3680
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
High-Risk Cancer, Locally Advanced Breast Cancer
Three Fraction Radiation to Induce Immuno-Oncologic Response
Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple negative and HER2-positive breast…
- Trial name
- TRIO (NCT03978663)
- Testing
- Neoadjuvant radiotherapy
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and…
- Conditions
- Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma, Locally Advanced Prostate Cancer, Unfavourable Intermediate Risk Prostate Cancer
- Trial name
- DAPROCA10 (NCT07343349)
- Testing
- Addition of focal boost and hypofractionation
- Where
- 3 sites in Denmark
- Volunteers
- 1,016 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
High Risk Locally Advanced Nasopharyngeal Carcinoma
TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma
We expect to conduct a clinical trial in high-risk locally advanced nasopharyngeal carcinoma patients to explore the efficacy and safety of sequential radical radiotherapy treatment after induction chemotherapy (TPC vs.
- Trial name
- NCT06561763
- Testing
- Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine, Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
- Volunteers
- 416 people
- Sponsor
- Sun Yat-sen University
Locally Advanced, High-Risk
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
This is a single arm, open-label, prospective clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and toripalimab (PD-1 antibody) for locally advanced rectal cancer (LARC) patients with high risk…
- Conditions
- Locally Advanced, High-Risk, Rectal Cancer, MSS
- Trial name
- NCT05877573
- Testing
- Toripalimab, short-term radiotherapy, Oxaliplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Neoadjuvant Therapy, High Risk Prostate Cancer
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
- Conditions
- Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
- Trial name
- NCT05406999
- Testing
- ADT, Abiraterone Acetate, Prednisolone tablets
- Where
- China
- Volunteers
- 900 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy
FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
The main cause of recurrence after surgical treatment of colorectal cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy.
- Conditions
- High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy, FOLFOXIRI Regimen
- Trial name
- NCT05018182
- Testing
- Oxaliplatin, Irinotecan, Folinic Acid
- Where
- China
- Volunteers
- 69 people
- Sponsor
- West China Hospital
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca